missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ ADAM22 Monoclonal Antibody (498805)

Mouse Monoclonal Antibody
Brand: Invitrogen™ MA524210
This item is not returnable.
View return policy
Description
In Western blots, no cross-reactivity with recombinant human ADAM8, 9, 10, 12, 15, 19, 23, 32, or 33 is observed. Reconstitute at 0.5 mg/mL in sterile PBS.
This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. This gene is highly expressed in the brain and may function as an integrin ligand in the brain. Alternative splicing results in several transcript variants.
Specifications
| ADAM22 | |
| Monoclonal | |
| 0.5 mg/mL | |
| PBS with 5% trehalose and No Preservative | |
| Q9P0K1 | |
| Adam22 | |
| CHO-derived recombinant human ADAM22 Gly26-His528. | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG2b |
| Immunoprecipitation, Western Blot | |
| 498805 | |
| Unconjugated | |
| Adam22 | |
| 2900022I03Rik; a disintegrin and metallopeptidase domain 22; a disintegrin and metalloprotease domain (ADAM) 22; a disintegrin and metalloprotease domain 22; a disintegrin and metalloproteinase; a disintegrin and metalloproteinase domain 22; ADAM; ADAM 22; ADAM metallopeptidase domain 22; Adam22; ADAMs; AI854032; Disintegrin and metalloproteinase domain-containing protein 22; MDC2; metalloendopeptidases; Metalloproteinase-disintegrin ADAM22-3; metalloproteinase-like, disintegrin-like, and cysteine-rich protein 2; MGC149832 | |
| Mouse | |
| Protein A/G | |
| RUO | |
| 53616 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction